Qingkaisha^® Rasagiline Mesylate Tablets are a second-generation irreversible and selective monoamine oxidase (MAO)-B inhibitor that prevents the breakdown of the neurotransmitter dopamine, used in the treatment of Parkinson's Disease (PD). Compared to Selegiline (the first-generation MAO-B inhibitor), it has 5-10 times stronger inhibitory effects, better efficacy, and higher safety. It is highly effective when used in combination with levodopa preparations for patients who experience treatment failure and end-of-dose fluctuations. The once-daily (1 mg/day) dosage regimen enhances patient adherence. Studies both domestically and internationally show that Rasagiline has potential disease-modifying effects, making it suitable for monotherapy in early-stage PD patients, as well as an add-on therapy for patients in middle and late stages of PD, contributing to comprehensive management of Parkinson's disease throughout its course. After its launch, Rasagiline has been recommended by authoritative guidelines both domestically and internationally. It is rapidly gaining market share among global PD treatment medications, becoming one of the primary therapeutic options.

Qingkaisha^® Rasagiline Mesylate Tablets were approved in July 2023 and are listed as a Category B product under the National Medical Insurance Directory. Offering the same quality as the originator drug at a more affordable price, Qingkaisha^® significantly reduces the financial burden for Parkinson’s patients and provides a cost-effective option for both monotherapy and combination therapy with levodopa.